Type 1 Diabetes Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 to 50 who live in Canada
• People who have been diagnosed with type 1 diabetes or a related condition called latent autoimmune diabetes in adults (LADA) for at least one year
• People who have been using an insulin pump, multiple daily insulin injections, or an automated insulin delivery system for at least 3 months
• People who are currently using a continuous glucose monitor (a device that tracks blood sugar levels throughout the day)
• People who have had at least one menstrual period in the last 40 days
• People who are willing to share their glucose monitor data (and insulin pump data if applicable) with the research team during the study period
• People who have access to a smartphone or tablet that can be used to track menstrual cycles
• People whose weight has been stable (less than 5% change) over the last 3 months

Who may not be able to join:

• People using a hormonal contraception method that stops periods, such as the Depo-Provera injection, a progestin-releasing intrauterine device, or an extended-cycle birth control pill
• People using certain older forms of regular insulin (such as Entuzity U500, Novolin ge Toronto, or Humulin R)
• People with significant kidney problems or nerve-related conditions such as uncontrolled gastroparesis (a condition affecting stomach emptying), as assessed by the study doctor
• People who have had a serious heart or blood vessel event (such as a heart attack or cardiac surgery) within the last 6 months
• People for whom a change in insulin type, glucose monitor, insulin pump, or automated insulin device is planned before the end of the study
• People who are planning to start, stop, or change their contraception method during the study
• People who expect to need regular high doses of acetaminophen (paracetamol) during the study (above 1g every 6 hours)
• People who are currently pregnant or actively trying to become pregnant
• People who are currently breastfeeding
• People with thyroid disease that is not well controlled, or whose thyroid treatment has not been stable for at least 6 weeks
• People who have had a severe low blood sugar episode within two weeks of screening for the trial
• People who have been hospitalised due to a severe high blood sugar episode in the last 3 months
• People currently using steroid (glucocorticoid) medications, except for low stable doses, inhaled steroids, or stable treatment for adrenal insufficiency
• People using certain medications that affect stomach emptying or certain diabetes tablets (such as Metformin or DPP-4 inhibitors), unless the dose has been stable for 3 months and no change is planned
• People using a class of diabetes medication called SGLT-2 inhibitors, unless the dose has been stable for at least 3 months, no change is planned, and appropriate ketone monitoring is being carried out
• People with other serious medical conditions that the study doctor believes would interfere with completing the study
• People who are planning a significant change in exercise habits or diet during the study period (for example, starting or stopping a sport, or making a major dietary change)
• People who expect to have repeated MRI scans or similar imaging during the study that would require removing the glucose monitor for more than 10 days
• People who, in the study doctor's opinion, are unlikely or unwilling to complete the study
• People taking thyroid medication (such as levothyroxine) whose dose has changed in the last 6 weeks

Important: Always verify eligibility with the trial site directly before applying.